Video

Dr. Burgess on the Integration of PARP Inhibitors in Prostate Cancer

Earle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses the integration of PARP inhibitors in advanced prostate cancer. 

The FDA approvals of the PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) in patients with advanced castration-resistant prostate cancer were significant additions to the armamentarium of available options for this patient population, Burgess says. Moreover, the percentage of patients that have underlying germline or somatic aberrations, or homologous recombination repair genes are particularly affected by these efficacious agents, based on the results from the phase 2 TRITON2 study (NCT02952534), Burgess explains.

In addition to efficacy, the availability of PARP inhibitors makes them a preferred choice for patients. Olaparib and rucaparib are given as oral treatments and have demonstrated improved safety compared with taxane-based chemotherapy, Burgess concludes.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center